ovx836
Vaccineexperimental
Clinical trial activity
7 trials · 9 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
6
Phase 3
0
Phase 4
0
Earliest trial started Jun 12, 2018 (NCT03594890)
Timeline
Indications
Mechanism of action
- Influenza A virusImmunity, active
Influenza A virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06582277 | Phase 2 | Oct 31, 2024 | Ghent University, Harmony Clinical Research, KCAS Bio, Osivax S.A.S |
| NCT05734040 | Phase 2 | May 10, 2023 | Novotech, Osivax S.A.S |
| NCT05569239 | Phase 2 | Apr 1, 2023 | Clinact, Osivax S.A.S, University of Paris |
| NCT05284799 | Phase 2 | May 9, 2022 | Harmony Clinical Research, Novotech, Osivax S.A.S |
| NCT05060887 | Phase 2 | Nov 15, 2021 | Ghent University, Osivax S.A.S |
| NCT04192500 | Phase 2 | Dec 31, 2019 | Ghent University, Osivax S.A.S |
| NCT03594890 | Phase 1 | Jun 12, 2018 | Aepodia, Osivax S.A.S, University of Antwerp |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (9)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Osivax S.A.S | For profit | 7 | 7 | 2 | 2018 |
| Ghent University | Academic/Hospital | 3 | 0 | 1 | 2019 |
| Harmony Clinical Research | For profit | 2 | 0 | 1 | 2022 |
| Novotech | For profit | 2 | 0 | 1 | 2022 |
| Aepodia | For profit | 1 | 0 | 1 | 2018 |
| Clinact | For profit | 1 | 0 | 1 | 2023 |
| KCAS Bio | For profit | 1 | 0 | 1 | 2024 |
| University of Antwerp | Academic/Hospital | 1 | 0 | 1 | 2018 |
| University of Paris | Academic/Hospital | 1 | 0 | 1 | 2023 |
9 organizations
Page 1 / 1